Tirzepatide works differently from semaglutide at the receptor level, and that difference is the main reason people ask about this page specifically instead of just reading our semaglutide page.

A dual-hormone mechanism, not just another GLP-1

Semaglutide activates a single hormone receptor, GLP-1. Tirzepatide activates two: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. This dual-agonist mechanism is the core scientific distinction between the two medications, not a marketing detail. In head-to-head and cross-trial comparisons, tirzepatide has produced higher average weight loss than injectable semaglutide, with some data showing roughly 20% average weight loss for tirzepatide compared to roughly 14% for semaglutide at peak doses. Individual results vary, and a higher average doesn’t guarantee a better result for any one person, which is exactly why a real evaluation matters more than a general statistic.

Two brand names, two different approvals

Tirzepatide is sold under two brand names depending on what it’s treating:

• Zepbound is FDA-approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition.
• Mounjaro is FDA-approved for type 2 diabetes.

Same active ingredient, different approved uses, similar to how Ozempic and Wegovy both contain semaglutide but carry different approvals. If your provider discusses Mounjaro for a weight-related use, that would be an off-label use of a diabetes-approved product, worth understanding clearly before you decide.

What a Heally provider evaluates

Miracle Leaf® does not conduct this evaluation. We refer interested patients to Heally, an independent telehealth platform whose own licensed providers review your health history, current medications, and weight-related conditions, and determine whether tirzepatide is a reasonable option for you specifically, typically starting at a low dose and increasing every few weeks as tolerated.

What to expect

The most commonly reported side effects mirror those of other GLP-1 and dual-agonist medications: nausea, diarrhea, vomiting, and other gastrointestinal symptoms, most noticeable when starting or after a dose increase. If you are weighing tirzepatide against semaglutide, our semaglutide page covers the single-receptor option in more depth, and our metformin page covers a lower-cost, non-injectable alternative some providers use instead of or alongside a GLP-1 or dual-agonist medication.

Sources

• Heally’s own published comparison of tirzepatide and semaglutide (getheally.com/patients/news/tirzepatide-vs-semaglutide), pulled 2026-07-23, for the mechanism and comparative efficacy figures referenced above
• FDA approval history for Zepbound (November 2023) and Mounjaro (May 2022), per public FDA and manufacturer approval records

Medically reviewed by REVIEW LATER - named medical reviewer pending. Last reviewed 2026-07-23.